share_log

Tonix Pharmaceuticals | 8-K: Tonix Pharmaceuticals Announces Transition to Fully Integrated Biopharmaceutical Company Expected on April 1, 2024

SEC announcement ·  Mar 19 20:06
Summary by Futu AI
Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, announced on March 19, 2024, its transition to a fully integrated pharmaceutical company effective April 1, 2024. This strategic move follows the acquisition of two migraine treatment products, Zembrace SymTouch and Tosymra, in June 2023. The company has been establishing the necessary commercial infrastructure to support these products. CEO Seth Lederman highlighted the transition as a significant milestone, preparing Tonix for the potential 2025 launch of Tonmya for fibromyalgia management, pending FDA approval. Tonmya has shown positive results in Phase 3 clinical trials. The announcement was made in a press release filed with the SEC and does not constitute a filing under the Securities Act of 1933 or the Exchange Act.
Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, announced on March 19, 2024, its transition to a fully integrated pharmaceutical company effective April 1, 2024. This strategic move follows the acquisition of two migraine treatment products, Zembrace SymTouch and Tosymra, in June 2023. The company has been establishing the necessary commercial infrastructure to support these products. CEO Seth Lederman highlighted the transition as a significant milestone, preparing Tonix for the potential 2025 launch of Tonmya for fibromyalgia management, pending FDA approval. Tonmya has shown positive results in Phase 3 clinical trials. The announcement was made in a press release filed with the SEC and does not constitute a filing under the Securities Act of 1933 or the Exchange Act.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.